Patents Assigned to AbbVie Inc.
  • METHODS FOR MODULATING PROTEIN GLYCOSYLATION PROFILES OF RECOMBINANT PROTEIN THERAPEUTICS USING MONOSACCHARIDES AND OLIGOSACCHARIDES
    Publication number: 20140271632
    Abstract: The present invention relates to the field of protein production, and in particular to methods and compositions for modulating glycosylation of proteins expressed in host cells.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: AbbVie, Inc.
    Inventors: Patrick Hossler, Sean McDermott, Christopher Racicot, Ivan Correia
  • Processes For The Preparation Of An Apoptosis-Inducing Agent
    Publication number: 20140275540
    Abstract: Provided herein is a process for the preparation of an apoptosis-inducing agent, and chemical intermediates thereof. Also provided herein are novel chemical intermediates related to the process provided herein.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: ABBVIE INC.
    Inventors: Vincent S. Chan, Alan C. Christesen, Timothy A. Grieme, Yi-Yin Ku, Mathew M. Mulhern, Yu-Ming M. Pu
  • PYRIDINE CDK9 KINASE INHIBITORS
    Publication number: 20140275011
    Abstract: Disclosed are compound of Formula (Ia), wherein R2, R12, R16, J, Q, X, Y and Z are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (Ia).
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: AbbVie Inc.
    Inventors: Anthony Mastracchio, Milan Bruncko, Chunqiu Lai, Julie M. Miyashiro, Zhi-Fu Tao, Keith W. Woods, Thomas D. Penning, Andrew J. Souers
  • AZAADAMANTANE FORMATE ESTER AND PROCESS FOR PREPARING AZAADAMANTANE DERIVATIVES
    Publication number: 20140275546
    Abstract: A compound, (4s)-1-azaadamantane-4yl formate ester, is described. In addition, a process is described for preparing (4s)-1-azaadamantane-4yl formate ester, aminothiadiazole-phenyl phosphate salt, bromothiadizole-phenyl or (4s)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.13,7]-decane dihydrogen citrate. Furthermore, a process is described, comprising step of hydrolyzing (4s)-1-azaadamantane-4yl formate ester to form (4s)-1-azaadamantan-4-ol HBr salt.
    Type: Application
    Filed: March 11, 2014
    Publication date: September 18, 2014
    Applicant: AbbVie Inc.
    Inventors: Albert Wayne KRUGER, Shuang CHEN, Steven Cramer CULLEN, James Joseph NAPIER
  • DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1 and/or IL-17
    Publication number: 20140271458
    Abstract: Engineered multivalent and multispecific binding proteins that bind IL-1? and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: AbbVie Inc.
    Inventors: Tariq Ghayur, JiJie Gu, Maria Harris, Carrie Goodreau, Sonal Saluja
  • FLUID APPLICATORS FOR USE WITH TOPICAL MEDICATIONS
    Publication number: 20140270897
    Abstract: Fluid applicators for use with topical medications are disclosed herein. An example apparatus includes a housing and a fluid container disposed inside the housing. The example apparatus also includes a pump assembly disposed inside the housing and fluidly coupled to the fluid container. The example apparatus further includes an applicator coupled to the housing. The applicator defines an outlet and has a surface to be in contact with an application site on a person. The surface is in fluid communication with the pump assembly via the outlet. The example apparatus also includes an actuator operatively coupled to the pump assembly. Movement of the actuator from a first position to a second position is to operate the pump to dispense a dose of the fluid onto the surface.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: ABBVIE INC.
    Inventors: Linas P. Laurusonis, Edward Naguit Abante, Bryan Eliot Rolfs, Ramana Malladi, Bhimaprasad Medhal, James Blaine Wolford, Olivier Franck Currat, Martin Rathgeber, Kieron Hiuhon Tse
  • PROTEIN PURIFICATION USING DISPLACEMENT CHROMATOGRAPHY
    Publication number: 20140275494
    Abstract: Disclosed herein are compositions and methods for the isolation and purification of proteins from a sample. In particular, the present invention relates to compositions and methods for isolating and purifying proteins incorporating a displacement chromatographic step. The present invention is also directed toward pharmaceutical compositions comprising one or more antibodies purified by a method described herein.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 18, 2014
    Applicant: ABBVIE INC.
    Inventors: Chen Wang, Germano Copploa
  • Compounds as cannabinoid receptor ligands
    Patent number: 8835475
    Abstract: The present application relates to isothiazolylidene containing compounds of Formula (I) wherein R1, R2, R3, R4, and L are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: September 16, 2014
    Assignee: AbbVie Inc.
    Inventors: William A. Carroll, Michael J. Dart, Teodozyj Kolasa, Tongmei Li, Derek W. Nelson, Meena Patel, Sridhar Peddi, Arturo Perez-Medrano, Xueqing Wang
  • 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide crystalline form 1
    Patent number: 8835647
    Abstract: 2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide Crystalline Form 1, ways to make it, compositions comprising it and made using it, and methods of treating patients having disease using it are disclosed.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: September 16, 2014
    Assignee: AbbVie Inc.
    Inventor: Lawrence Kolaczkowski
  • IL-17 binding proteins
    Patent number: 8835610
    Abstract: Proteins that bind IL-17 and/or IL-17F are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: September 16, 2014
    Assignee: Abbvie Inc.
    Inventors: Chung-Ming Hsieh, Margaret Hugunin, Yuliya Kutskova, John E. Memmott, Jennifer M. Perez, Suju Zhong, Edit Tarcsa, Anca Clabbers
  • ISOLATION AND PURIFICATION OF ANTIBODIES USING PROTEIN A AFFINITY CHROMATOGRAPHY
    Publication number: 20140255423
    Abstract: Disclosed herein are methods for the isolation and purification of antibodies wherein the use of an affinity chromatographic step results in an antibody composition sufficiently pure for pharmaceutical uses. The methods described herein comprise pH viral reduction/inactivation, ultrafiltration/diafiltration, affinity chromatography, preferably Protein A affinity, ion exchange chromatography, and hydrophobic chromatography. Further, the present invention is directed toward pharmaceutical compositions comprising one or more antibodies of the present invention.
    Type: Application
    Filed: March 26, 2014
    Publication date: September 11, 2014
    Applicant: AbbVie Inc.
    Inventors: Robert K. Hickman, Qing Huang, Cheryl L. Weed, Scott T. Ennis, Barbara Perilli-Palmer, Min Wan
  • Specific binding proteins and uses thereof
    Publication number: 20140255410
    Abstract: The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.
    Type: Application
    Filed: December 11, 2012
    Publication date: September 11, 2014
    Applicant: ABBVIE INC.
    Inventors: Lloyd J. Old, Terrance Grant Johns, Con Panousis, Andrew Mark Scott, Christoph Renner, Gerd Ritter, Achim Jungbluth, Elisabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice
  • Cyclopropyl amine derivatives
    Patent number: 8829041
    Abstract: Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: September 9, 2014
    Assignee: AbbVie Inc.
    Inventors: Huaqing Liu, Lawrence A. Black, Youssef L. Bennani, Marlon D. Cowart
  • Pyrrolopyridine inhibitors of kinases
    Patent number: 8822446
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R1a, R1b, R1c, X, and Y are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as Cdc7 and methods of treating diseases such as cancer.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: September 2, 2014
    Assignee: AbbVie Inc.
    Inventors: Thomas D. Penning, Keith W. Woods, Chunqiu Lai, Yunsong Tong, Alan S. Florjancic
  • Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
    Patent number: 8822645
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Grant
    Filed: July 8, 2009
    Date of Patent: September 2, 2014
    Assignee: AbbVie Inc.
    Inventors: Tariq Ghayur, Jijie Gu, Peter C. Isakson
  • METHODS AND COMPOSITIONS FOR MODULATING AN IMMUNE RESPONSE
    Publication number: 20140242077
    Abstract: Provided are multispecific binding proteins and methods for using these multispecific binding proteins to modulate the activation state of immune cells, such as T-cells (e.g., cytotoxic T-cells). Also provided are methods of modulating an immune response (e.g., cell killing by cytotoxic T-cells) in a subject (e.g., a human subject). Also provided are nucleic acids, expression vectors and host cells encoding the multispecific binding proteins.
    Type: Application
    Filed: January 23, 2014
    Publication date: August 28, 2014
    Applicant: AbbVie, Inc.
    Inventors: Chee-Ho CHOI, Qingfeng TAO, Philip BARDWELL, Tariq GHAYUR
  • CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF
    Publication number: 20140243340
    Abstract: The present invention features compounds of formula I or pharmaceutically acceptable salts, solvates or prodrugs thereof, and methods of using the same to inhibit the metabolizing activities of CYP enzymes. The present invention also features methods of using these compounds, salts, solvates or prodrugs to improve the pharmacokinetics of drugs that are metabolized by CYP enzymes.
    Type: Application
    Filed: May 8, 2014
    Publication date: August 28, 2014
    Applicant: AbbVie Inc.
    Inventors: Larry L. Klein, Hui-Ju CHEN, Ming C. YEUNG, Charles A. Flentge, John T. Randolph, Peggy Huang, Douglas K. Hutchinson, Dale J. Kempf
  • HIGH-THROUGHPUT SYSTEM AND METHOD FOR IDENTIFYING ANTIBODIES HAVING SPECIFIC ANTIGEN BINDING ACTIVITIES
    Publication number: 20140243228
    Abstract: System and methods are disclosed for identifying and isolating antibodies with specific affinity with an antigen of interest. Multiple DNA libraries encoding antibodies or their fragments are designed such that the encoded antibodies from different libraries are tagged differently. These libraries may be transformed into yeast cells. The variants of the antibodies are displayed on the surface of the yeast cells and flow cytometry may be used to sort the cells based on antigen affinity and the different tags on the antibodies. By allowing multiple libraries to be screened simultaneously, the disclosed methods help improve the efficiency of affinity.
    Type: Application
    Filed: December 27, 2013
    Publication date: August 28, 2014
    Applicant: AbbVie, Inc.
    Inventors: Lorenzo BENATUIL, Jennifer PEREZ, Chung-Ming HSIEH
  • Lactam acetamides as calcium channel blockers
    Patent number: 8815869
    Abstract: The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein Ar1, n, R1, X and Y are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: August 26, 2014
    Assignee: AbbVie Inc.
    Inventors: Irene Drizin, George Doherty, Pramila A. Bhatia, Andrew O. Stewart
  • Compounds that inhibit TRPV1 and uses thereof
    Patent number: 8815930
    Abstract: Compounds of formula (I) wherein R3, R7, R9 and L are defined in the description are TRPV1 antagonists that exhibit low inhibitory activity against CYP3A4. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Grant
    Filed: June 14, 2010
    Date of Patent: August 26, 2014
    Assignee: AbbVie Inc.
    Inventors: Chih-hung Lee, Richard J. Perner, Brian S. Brown, John F. Darbyshire